# Dihydroartemisinin Promotes N1 Polarization of Tumor-Associated Neutrophils and Enhances Their Anti-Tumor Activity via Hub Gene Modulation

**Authors:** Wenjia Guo, Yu’e Liu, Wencong Ma, Jinghan Wang, Bingdi Chen, Lieying Fan

PMC · DOI: 10.3390/ph19010088 · 2026-01-01

## TL;DR

This study shows that dihydroartemisinin (DHA) can shift tumor-associated neutrophils toward an anti-tumor state, potentially improving cancer treatment.

## Contribution

The paper identifies DHA as a novel agent that modulates tumor-associated neutrophil polarization through specific hub gene regulation.

## Key findings

- DHA promotes N1 polarization of neutrophil-like cells by upregulating anti-tumor markers like TNF and IL1B.
- DHA-treated cells show enhanced cytotoxic activity against hepatocellular carcinoma cells.
- Molecular docking suggests DHA interacts with key hub proteins involved in TAN polarization.

## Abstract

Background: Tumor-associated neutrophils (TANs) exhibit remarkable functional plasticity within tumor microenvironment (TME), with N1-like subtypes promoting anti-tumor immunity and N2-like subtypes facilitating tumor progression. Despite their critical role in cancer immunology, strategies to selectively modulate TAN polarization remain limited. Methods: We integrated transcriptomic analyses of TAN subtypes to identify potential hub molecules. Molecular docking and experimental assays were used to evaluate DHA’s effect on neutrophil-like cell polarization. Results: Hub genes (TNF, IL1B, PTGS2, BCL2A1, MSR1, ACOD1, CXCL16, CLEC10A, and SOCS3) were identified, with TNF serving as a potential core regulator. Molecular docking indicated that DHA forms stable interactions hub proteins. Experimentally, DHA treatment of neutrophil-like dNB4 cells promoted N1 polarization, evidenced by upregulation of TNF, IL1B, PTGS2, BCL2A1, MSR1, ACOD1, CXCL16, and N1 markers PD-L1 and NOX2, and downregulation of N2 marker CEACAM8 and hub genes CLEC10A and SOCS3. Functional assays demonstrated that DHA-treated cells exhibited increased secretion of TNF, IL1β, ROS, and PD-L1, accompanied by enhanced cytotoxic activity against hepatocellular carcinoma cells in a co-culture system. Conclusions: These findings reveal the molecular mechanisms underlying TAN polarization, and establish DHA as a potent immunomodulatory agent capable of reshaping TANs toward an anti-tumor phenotype.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], IL1B (interleukin 1 beta) [NCBI Gene 3553], PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743], BCL2A1 (BCL2 related protein A1) [NCBI Gene 597], MSR1 (macrophage scavenger receptor 1) [NCBI Gene 4481], ACOD1 (aconitate decarboxylase 1) [NCBI Gene 730249], CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191], CLEC10A (C-type lectin domain containing 10A) [NCBI Gene 10462], SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021], CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088], CD274 (CD274 molecule) [NCBI Gene 29126], CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536]
- **Chemicals:** DHA (PubChem CID 15608515), dihydroartemisinin (PubChem CID 107770)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, ACOD1 (aconitate decarboxylase 1) [NCBI Gene 730249] {aka CAD, IRG1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CLEC10A (C-type lectin domain containing 10A) [NCBI Gene 10462] {aka CD301, CLECSF13, CLECSF14, DC-ASGPR, HML, HML2}, CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191] {aka CXCLG16, SR-PSOX, SRPSOX}, SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021] {aka ATOD4, CIS3, Cish3, SOCS-3, SSI-3, SSI3}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, MSR1 (macrophage scavenger receptor 1) [NCBI Gene 4481] {aka CD204, SCARA1, SR-A, SR-AI, SR-AII, SR-AIII}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), Tumor (MESH:D009369), cytotoxic (MESH:D064420)
- **Chemicals:** Dihydroartemisinin (MESH:C039060), ROS (-), DHA (MESH:C027493)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12844713/full.md

---
Source: https://tomesphere.com/paper/PMC12844713